Cancer Clinical Trials:
What the Public Health and Primary Care Provider Need to Know
Originally presented on December 15, 2011
Yelena Novik, MD, FACP
Assistant Professor; Medical Director-Clinical Trials Office
Department of Medicine (Residency Program)
NYU Cancer Institute
Michael L. Pearl, MD, FACOG, FACS
Professor and Director
Division of Gynecological Oncology
Stony Brook University Hospital
Only 3 – 5% of adult cancer survivors participate in clinical trials; older adults and minorities are even less likely to do so. Increased participation in cancer-related trials benefits society by helping to develop and test the safety of new cancer treatments, and benefits participants who receive high quality cancer care. This Public Health Live webcast will address psychosocial, financial and other barriers to recruitment into cancer clinical trials, highlight the disparities that exist in terms of participation and identify NYS resources and strategies which may help lower barriers and reduce disparities.
After watching this broadcast participants will be able to:
- Understand basic principles relating to cancer clinical trials, including purpose/limitations of Phase I, II and III clinical trials.
- Understand the benefits associated with cancer clinical trials, using lessons learned and best practices gleaned from pediatric cancer clinical trials as a model.
- Understand barriers to participation in clinical trials among adults at-risk for or affected with cancer and identify disparities in clinical trial participation.
- Identify strategies to improve enrollment into cancer clinical trials, across all populations.
This program was offered in partnership with: Cancer Support and Survivorship Initiatives at The New York State Department of Health, Bureau of Chronic Disease Control